- Home
- HOTH vs ATHA Comparison
HOTH vs ATHA Comparison
Compare HOTH & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- ATHA
- Stock Information
- Founded
- HOTH 2017
- ATHA 2011
- Country
- HOTH United States
- ATHA United States
- Employees
- HOTH N/A
- ATHA N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- HOTH Health Care
- ATHA Health Care
- Exchange
- HOTH Nasdaq
- ATHA Nasdaq
- Market Cap
- HOTH 15.6M
- ATHA 14.8M
- IPO Year
- HOTH 2019
- ATHA 2020
- Fundamental
- Price
- HOTH $1.76
- ATHA $3.85
- Analyst Decision
- HOTH Strong Buy
- ATHA Hold
- Analyst Count
- HOTH 3
- ATHA 1
- Target Price
- HOTH $4.00
- ATHA $5.00
- AVG Volume (30 Days)
- HOTH 2.3M
- ATHA 37.6K
- Earning Date
- HOTH 11-11-2025
- ATHA 11-06-2025
- Dividend Yield
- HOTH N/A
- ATHA N/A
- EPS Growth
- HOTH N/A
- ATHA N/A
- EPS
- HOTH N/A
- ATHA N/A
- Revenue
- HOTH N/A
- ATHA N/A
- Revenue This Year
- HOTH N/A
- ATHA N/A
- Revenue Next Year
- HOTH N/A
- ATHA N/A
- P/E Ratio
- HOTH N/A
- ATHA N/A
- Revenue Growth
- HOTH N/A
- ATHA N/A
- 52 Week Low
- HOTH $0.65
- ATHA $2.20
- 52 Week High
- HOTH $3.80
- ATHA $8.26
- Technical
- Relative Strength Index (RSI)
- HOTH 56.70
- ATHA 49.75
- Support Level
- HOTH $1.75
- ATHA $3.53
- Resistance Level
- HOTH $2.12
- ATHA $4.49
- Average True Range (ATR)
- HOTH 0.18
- ATHA 0.30
- MACD
- HOTH 0.02
- ATHA 0.02
- Stochastic Oscillator
- HOTH 55.41
- ATHA 37.38
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.